State-of-the-art facility in Yaroslavl demonstrates Takeda's long-term
commitment to the Russian market
Plant expected to be fully operational in 2014, supplying high quality
tablet and sterile liquid products for the local market
€75 million investment
ZURICH, Sept. 11, 2012 /CNW/ - Takeda Pharmaceutical International GmbH
("Takeda") today announced the completion of construction at its
pharmaceutical manufacturing facility in Yaroslavl, Russia. The
Company has invested approximately €75 million in the 24,000m2 production plant, which is expected to be fully operational by 2014.
Takeda was one of the first major international companies to have
invested in high quality pharmaceutical manufacturing in Russia,
demonstrating its long-term commitment to the market. Based on sales
Takeda is the 7th largest pharmaceutical company in Russia. According to IMS Health,
Russian pharmaceutical sales totaled $14.7 billion* in 2011, making it the 11th largest pharmaceutical market in the world. Market sales in Russia/CIS
are expected to grow at a compound annual rate of 11%* between 2012 and 2016. Takeda plans to outgrow the market with an
annual growth rate of 15% over the same period.
The Yaroslavl facility will enable Takeda to meet demand in Russia,
initially Cardiomagnyl, Actovegin and Calcium tablets. It will lead to
creation of initially around 200 positions for highly qualified
managers and technical staff.
The plant, which is approximately 280 kilometers from Moscow, was
constructed on time and on budget to local and international GMP
standards and adheres to the latest safety and environmental standards.
It will have the initial capacity to manufacture 90 million sterile
ampoules and more than two billion tablets per year. Liquid sterile
production includes solution preparation, washing of ampoules,
sterilization, filling, inspection, and packaging. Solid production
will encompass all stages, from weighing, mixing and granulation
through compression, coating, and packaging.
"The completion of this ambitious project further demonstrates Takeda's
transition into a truly global business, and strategic investment into
key emerging markets such as Russia is a major part of this strategy."
said Yasuchika Hasegawa, President & Chief Executive Officer of Takeda
Pharmaceutical Company Limited. "Russia is our largest emerging market
in terms of revenues, and is expected to contribute significantly to
our growth over the next few years. The Yaroslavl facility will enable
us to provide locally produced pharmaceutical products to patients and
clinicians, as well as bringing significant benefits to the Yaroslavl
and Russian economy."
"Takeda is one of the flagship companies in Yaroslavl's pharmaceutical
cluster and is the first major international pharmaceutical company to
invest in a new world class manufacturing facility in the region,"
added Sergey Yastrebov, the Governor of Yaroslavl Region. "This project
is an excellent example of the benefits that international investment
can bring to the Russian economy. Takeda is working closely with
Russian companies to build the plant, and will create hundreds of high
quality jobs for Russian people in the future."
[*]Data Source:© 2012 IMS Health. All rights reserved. Estimated based on
Market Prognosis Reprinted with permission
About Takeda Pharmaceuticals International GmbH
Takeda Pharmaceuticals International GmbH, headquartered in Zurich, is a
wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As
the largest pharmaceutical company in Japan and a leader in the global
industry, Takeda's mission is to strive toward better health for
patients worldwide through leading innovation in medicine. It has a
commercial presence in around 70 countries, with particular strength in
Asia, North America, Europe and fast-growing emerging markets including
Latin America, Russia-CIS and China. Takeda is ranked 12th by global Rx
sales, 14th in the BRIC countries and 18th in Europe. Areas of focus
include cardiovascular and metabolic diseases, immunology and
respiratory diseases, oncology and central nervous system diseases,
among others. Through the integration of Millennium Pharmaceuticals and
Nycomed, Takeda has been transforming itself, broadening its
therapeutic expertise and geographic outreach.
Additional information about Takeda is available through its corporate
SOURCE: Takeda Pharmaceuticals International GmbH
For further information:
Media Contacts: Takeda Pharmaceutical Company Limited, Public Relations and Investor Relations, +81-3-3278-2037; Russian media, Georgy Soustin, +7-495-933-5511, email@example.com; European media, Tobias Cottmann, +41-79-217-72-52, firstname.lastname@example.org